We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In cooperation with Association of Corporate Counsel
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 350

Patent claiming one medicinal ingredient not found to have sufficient product specificity to be listed against a drug containing two medicinal ingredients

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • April 29 2015

The Court of Appeal has dismissed Viiv Healthcare’s appeal of a Prothonotary’s decision (2014 FC 328; upheld by the Federal Court: 2014 FC 893

Supreme Court dismisses leave application relating to utility and sound prediction

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • April 29 2015

The Supreme Court has dismissed Apotex’s leave to appeal a PM(NOC) decision (2014 FCA 250) that related to utility and sound prediction. The Supreme

Formulation patent found not to be infringed as a redacted excipient was not a “pentahydric or hexahydric alcohol”

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • April 22 2015

Apotex has successfully alleged that Teva’s patent to “Stable Compositions Containing Rasagiline” will not be infringed by Apotex’s use of a

Respondent’s evidence in PM(NOC) case not struck - found to be responsive and did not raise new allegations or facts

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • April 29 2015

Shire has lost its appeal regarding the dismissal of its motion to strike certain affidavit evidence submitted by the respondent Cobalt in an

Ramipril section 8 appeal dismissed from the bench by the Supreme Court of Canada

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • April 22 2015

On Monday, April 20, 2015, the Supreme Court of Canada heard the appeal of 2014 FCA 68, relating to the issue of damages under section 8 of the

Court enforces a settlement agreement even though one party denied such an agreement existed

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • April 22 2015

Allergan brought a motion to enforce a settlement agreement that Apotex denies was made. Allergan had sued for infringement and Apotex wrote a

Patent found valid and infringed even if the method of infringement was not in the minds of the inventors

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • April 13 2015

AstraZeneca sued Apotex for infringement of its patent relating to the formulation of the drug omeprazole. Apotex argued invalidity and

Doctrine of bona fide purchaser for value without notice applies to patent rights

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • February 6 2012

This case involves a dispute over who owned certain patent rights

Patent found invalid on basis of lack of utility, sound prediction and obviousness

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • January 3 2012

This decision relates to an impeachment action and an infringement action that were consolidated

Statements in a generic’s Product Monograph were not found to amount to an inducement to infringe

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • April 13 2015

The Court has allowed a motion to strike portions of an application pursuant to Paragraph 6(5)(b) of the PM(NOC) Regulations. The generic respondent